The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Do older patients with FLT3 AML benefit from midostaurin plus chemotherapy?

During the 62nd ASH Annual Meeting and Exposition, the AML Hub was pleased to speak to Jorge Sierra, Hospital de la Santa Creu i Sant Pau, Barcelona, ES, about a combinational treatment regimen with midostaurin and chemotherapy for older patients with FLT3 AML.

Do older patients with FLT3 AML benefit from midostaurin plus chemotherapy?

Sierra summarizes key findings from published and ongoing trials, demonstrating the benefit of midostaurin plus chemotherapy in older patients with AML who are fit for intensive chemotherapy.

Sierra kindly gave his interview in Spanish, with the title '¿Los pacientes mayores con buen estado general ("fit") se beneficial de quimioterapia intensiva y inhibidores de FLT3?'

 

Share: